Merck & Co., Inc. (MRK) To absorb $1.1 Billion In Net debt On Cubist Pharmaceuticals Inc. (CBST) Acquisition
Merck & Co., Inc.
Cubist Pharmaceuticals Inc (CBST)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 2. | Andromeda Capital Larry Motola | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | VenBio Select Advisor Kurt Von Emster | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.78 | 5,000 | Director | 5,883 | 2011-11-04 | Filing | |
| $38.66 | 1,300 | Director | 3,500 | 2011-10-26 | Filing | |
| $38.66 | 200 | Director | 2,200 | 2011-10-26 | Filing | |
| $21.00 | 1,115 | Director | 5,500 | 2010-07-21 | Filing | |
| $16.94 | 2,700 | Director | 3,380 | 2009-05-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.50 | 400 | Officer | 27,598 | 2014-10-01 | Filing | |
| $65.68 | 22,225 | Officer | 27,998 | 2014-10-01 | Filing | |
| $65.11 | 25,500 | Officer | 50,223 | 2014-10-01 | Filing | |
| $65.88 | 38,326 | Officer | 18,136 | 2014-08-19 | Filing | |
| $65.00 | 9,000 | Director | 5,951 | 2014-08-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% |
News See All
Trius Therapeutics, Inc. (TSRX), Cubist Pharmaceuticals Inc (CBST), Pfizer Inc. (PFE): A Portfolio Of Potential
After the market closed on July 30, antibiotic expert Cubist Pharmaceuticals Inc (NASDAQ:CBST) announced two acquisitions worth up to a combined $1.6 billion.
Hedge Funds Are Dumping Dr. Reddy's Laboratories Limited (ADR) (RDY)
To many of your fellow Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY) investors, hedge funds are perceived as overrated, outdated investment vehicles of an era lost to time.
Hedge Funds Are Betting On United Therapeutics Corporation (UTHR)
If you were to ask many traders, hedge funds are viewed as useless, outdated financial tools of a forgotten age.
The Medicines Company (MDCO), United Therapeutics Corporation (UTHR): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many investors, hedge funds are perceived as bloated, outdated financial vehicles of a forgotten age.
Hedge Funds Are Crazy About Endo Health Solutions Inc (ENDP)
To many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Hedge Funds Are Betting On Warner Chilcott Plc (WCRX)
In today’s marketplace, there are tons of indicators investors can use to track the equity markets. A couple of the most underrated are hedge fund and insider trading sentiment.
Cubist Pharmaceuticals Inc (CBST): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
If you were to ask many of your fellow readers, hedge funds are assumed to be overrated, outdated financial tools of an era lost to time.
Cubist Pharmaceuticals Inc (CBST), Trius Therapeutics, Inc. (TSRX): How Could This Deal Shake Up an Entire Industry?
With two simultaneous moves that have set the pharmaceutical world on fire, Cubist Pharmaceuticals Inc (NASDAQ:CBST) has triumphantly announced its arrival on the global stage.
Cubist Pharmaceuticals Inc (CBST), Forest Laboratories, Inc. (FRX): Marketed Drugs, Strong Pipeline, Long Term Growth Stock
In June this year, a drug candidate from Cubist Pharmaceuticals Inc (NASDAQ:CBST) received fast track status from the FDA.